Nipocalimab Receives FDA Fast Track Designation for Systemic Lupus Erythematosus

The US Food and Drug Administration (FDA) has granted Fast Track designation to nipocalimab for the treatment of adults with systemic lupus erythematosus (SLE), Johnson & Johnson has announced.¹

The decision is supported by data from the phase 2b JASMINE study, in which the investigational FcRn blocker met its primary composite disease activity endpoint and multiple secondary outcomes, including signals consistent with glucocorticoid-sparing potential, although a full data readout is still anticipated at a future medical meeting.²

"Systemic lupus erythematosus is a serious, complex disease that affects many aspects of a patient's life, and treatment options remain limited," Richard Furie, MD, Chief of the Division of Rheumatology at Northwell Health, said in the comapny’s states.¹ "Progress like this brings renewed hope for more targeted therapies and meaningful outcomes for people living with this devastating disease."

Trial Design and Primary Outcomes

JASMINE (NCT04882878) was a 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study enrolling 228 adults with active SLE.² The primary endpoint was the proportion of patients achieving an SLE Responder Index 4 (SRI-4) composite response at week 24 versus placebo. SRI-4 integrates improvement on the SELENA-SLEDAI disease activity index, no worsening on Physician Global Assessment, and no new severe organ domain involvement per the BILAG 2004 index.²

Nipocalimab met the primary endpoint, producing a statistically significant increase in SRI-4 composite responders compared with placebo at week 24.² The study also met key secondary and exploratory endpoints, including those assessing steroid-sparing potential.² The safety and tolerability profile was consistent with prior phase 2 evaluations of nipocalimab, with no new safety signals identified; however, granular adverse event data and dose-arm–specific response rates have not yet been published.²

This readout from JASMINE represents the first positive randomized controlled trial of an investigational FcRn blocker in active SLE.² Based on these results, Johnson & Johnson has initiated enrollment in the phase 3 GARDENIA study (NCT07438496) of adults with active SLE.¹

SLE is a chronic, systemic autoimmune disease in which pathogenic IgG autoantibodies drive inflammation and tissue injury across multiple organ systems, including the skin, joints, kidneys, heart, lungs, and central nervous system.¹ The treatment landscape, while expanding, remains limited relative to disease heterogeneity. Hydroxychloroquine is a cornerstone of SLE management.³ Among approved biologics, belimumab (Benlysta), an anti-BLyS antibody, and anifrolumab (Saphnelo), a type I interferon receptor antagonist, are the two agents with specific FDA approval for SLE, with current ACR/EULAR guidance positioning both as first-line biologic options for moderate to high disease activity.⁴˒⁵ Voclosporin is approved specifically for lupus nephritis. Rituximab is used off-label in refractory cases.⁵ Despite these options, many patients remain on chronic glucocorticoids, with attendant risks of infection, osteoporosis, cardiovascular disease, and metabolic complications. An agent capable of reducing disease activity while enabling steroid tapering would address a recognized gap across the SLE population.

Mechanism of Action and Drug-Class Background

Nipocalimab is a fully human IgG1 monoclonal antibody that binds the neonatal Fc receptor (FcRn) with high affinity, blocking IgG recycling and thereby reducing circulating IgG levels, including the pathogenic autoantibodies that contribute centrally to SLE and other autoantibody-driven diseases, while leaving IgM, IgA, and complement-mediated functions intact.¹ This selective mechanism distinguishes it from broader immunosuppressive approaches and from agents targeting upstream immune pathways such as B-cell survival or interferon signaling.

The FcRn inhibitor class also includes efgartigimod (Vyvgart; argenx), approved for generalized myasthenia gravis (gMG) and under evaluation in lupus nephritis, and rozanolixizumab (Rystiggo; UCB), approved for gMG. Nipocalimab differs from efgartigimod in that it is a full-length monoclonal antibody rather than an engineered Fc fragment, a distinction the developer argues may have implications for placental FcRn blockade in maternal-fetal indications.⁵

The SLE Fast Track designation is nipocalimab's fifth from the FDA, following prior designations for hemolytic disease of the fetus and newborn (HDFN), warm autoimmune hemolytic anemia, gMG, fetal and neonatal alloimmune thrombocytopenia (FNAIT), and Sjögren's disease.¹ The agent also holds Breakthrough Therapy designation for HDFN and Sjögren's disease. In April 2025, nipocalimab received FDA approval under the brand name IMAAVY for gMG in adults and pediatric patients aged 12 years and older, supported by data from the phase 3 VIVACITY-MG3 trial.⁶

Outstanding questions include the optimal nipocalimab dose for phase 3 advancement, the durability of SRI-4 response through week 52, the clinical magnitude and practical feasibility of glucocorticoid tapering, and the long-term safety profile of sustained FcRn blockade and attendant IgG reduction.

References

1. Johnson & Johnson. Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus. Press release. March 3, 2026. https://www.jnj.com/media-center/press-releases

2. Johnson V. Nipocalimab reduces SLE disease activity, meeting JASMINE study end point. Rheumatology Live. Article. Published January 16, 2026. https://www.rheum-live.com/view/nipocalimab-reduces-sle-disease-activity-jasmine-study-end-point

3. Gatto M, Zen M, Cruciani C, Iaccarino L, Doria A. Navigating the landscape of SLE treatment: an expert viewpoint on the rationality and limitations of early biologic intervention. Autoimmun Rev. 2024;23(10):103612. https://doi.org/10.1016/j.autrev.2024.103612

4. Ząbczyńska M, Sobczyk M, Krawczyk-Ożóg A, et al. Advances in targeted therapy for systemic lupus erythematosus: current treatments and novel approaches. Int J Mol Sci. 2025;26(3):929. https://doi.org/10.3390/ijms26030929

5. AllSci. J&J's nipocalimab bags 5th FDA Fast Track indication with nod for lupus. Published March 3, 2026. https://allsci.com/news/jjs-nipocalimab-bags-5th-fda-fast-track-indication-with-nod-for-lupus/

6. Derman C. FDA approves nipocalimab for generalized myasthenia gravis for adults, children. HCPLive. Article. Published April 30, 2025. https://www.hcplive.com/view/fda-approves-nipocalimab-generalized-myasthenia-gravis-for-adults-children